TW200640497A - Pharmaceutical formulations and methods of use - Google Patents
Pharmaceutical formulations and methods of useInfo
- Publication number
- TW200640497A TW200640497A TW095102217A TW95102217A TW200640497A TW 200640497 A TW200640497 A TW 200640497A TW 095102217 A TW095102217 A TW 095102217A TW 95102217 A TW95102217 A TW 95102217A TW 200640497 A TW200640497 A TW 200640497A
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical formulations
- release component
- methods
- component
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention relates to new pharmaceutical formulations, and to new medical uses, of gabapentin and pregabalin. The formulations may comprise up to three components including an immediate release component, a sustained release component and a delayed release component. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration in a human subject.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64585705P | 2005-01-21 | 2005-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200640497A true TW200640497A (en) | 2006-12-01 |
Family
ID=36692870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095102217A TW200640497A (en) | 2005-01-21 | 2006-01-20 | Pharmaceutical formulations and methods of use |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1838291A4 (en) |
JP (1) | JP2008528494A (en) |
KR (1) | KR20070116588A (en) |
CN (1) | CN101137352A (en) |
AR (1) | AR062647A1 (en) |
AU (1) | AU2006206423A1 (en) |
BR (1) | BRPI0614021A2 (en) |
CA (1) | CA2595470A1 (en) |
IL (1) | IL184735A0 (en) |
MX (1) | MX2007008833A (en) |
TW (1) | TW200640497A (en) |
WO (1) | WO2006078811A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA94979C2 (en) | 2006-12-22 | 2011-06-25 | Рекордати Айеленд Лимитед | Combination therapy for lower urinary tract disorders with α2δ AND NSAIDs |
US8454993B2 (en) | 2007-11-23 | 2013-06-04 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
AU2008328548B2 (en) * | 2007-11-23 | 2014-05-15 | Grunenthal Gmbh | Tapentadol compositions |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
MX2013007884A (en) | 2011-01-07 | 2013-09-13 | Elcelyx Therapeutics Inc | Chemosensory receptor ligand-based therapies. |
ES2755075T3 (en) * | 2011-05-05 | 2020-04-21 | Hennig Arzneimittel Gmbh&Co Kg | Pharmacological form for the targeted release of active ingredients |
KR101438546B1 (en) * | 2011-08-26 | 2014-09-17 | 근화제약주식회사 | Controlled-release formulations comprising pregabalin |
WO2013100873A1 (en) * | 2011-12-19 | 2013-07-04 | Mahmut Bilgic | Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer) |
CA2860669C (en) | 2012-01-06 | 2022-05-03 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
EA201491335A1 (en) | 2012-01-06 | 2015-04-30 | Элселикс Терапьютикс, Инк. | BIGUANID COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISORDERS |
KR102221846B1 (en) * | 2014-04-07 | 2021-02-26 | 영진약품 주식회사 | Pharmaceutical composition of pregabalin with improved stability and method for preparing thereof |
JP6665099B2 (en) * | 2014-08-29 | 2020-03-13 | わかもと製薬株式会社 | Lactic acid bacteria-containing composition |
CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
EP3302425A4 (en) * | 2015-05-26 | 2018-12-26 | Isa Odidi | Controlled extended release pregabalin |
CN109152772B (en) * | 2016-04-19 | 2021-09-28 | 康纳里斯研究院股份公司 | Oral pharmaceutical composition of nicotinamide |
CA3030105A1 (en) * | 2016-07-17 | 2018-01-25 | Mapi Pharma Ltd. | Extended release dosage forms of pregabalin |
JP6919119B2 (en) * | 2017-01-23 | 2021-08-18 | 日新製薬株式会社 | A compressed solid pharmaceutical composition containing a γ-aminobutyric acid derivative substituted at the 3-position. |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
CN112023032B (en) * | 2020-09-14 | 2022-03-18 | 广东鼎信医药科技有限公司 | Pharmaceutical composition containing digestive enzyme and preparation method thereof |
MX2022015331A (en) | 2020-12-04 | 2023-02-01 | Laboratorios Silanes S A De C V | Stable coated solid pharmaceutical composition of an opioid analgesic and an anti-epileptic for pain. |
CN116898819B (en) * | 2023-06-09 | 2024-02-06 | 则正(上海)生物科技有限公司 | Pregabalin sustained release agent and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
WO1998029095A2 (en) * | 1997-01-03 | 1998-07-09 | Elan Corporation, Plc | Sustained release cisapride mini-tablet formulation |
FR2781793B1 (en) * | 1998-08-03 | 2001-07-20 | Prographarm Lab | PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES |
KR20040081446A (en) * | 2002-01-04 | 2004-09-21 | 아이박스 리서치, 인코포레이티드 | Drug delivery system for sustained delivery of glipizide |
EP2316469A1 (en) * | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
JP2008530131A (en) * | 2005-02-15 | 2008-08-07 | ジャズ、ファーマシューティカルズ、インコーポレイテッド | Dosage forms and methods for sustained release of substituted pyrazine compounds |
-
2006
- 2006-01-20 JP JP2007552260A patent/JP2008528494A/en active Pending
- 2006-01-20 KR KR1020077019105A patent/KR20070116588A/en not_active Application Discontinuation
- 2006-01-20 BR BRPI0614021-1A patent/BRPI0614021A2/en not_active IP Right Cessation
- 2006-01-20 CA CA002595470A patent/CA2595470A1/en not_active Abandoned
- 2006-01-20 CN CNA2006800065476A patent/CN101137352A/en active Pending
- 2006-01-20 AR ARP060100226A patent/AR062647A1/en not_active Application Discontinuation
- 2006-01-20 AU AU2006206423A patent/AU2006206423A1/en not_active Abandoned
- 2006-01-20 MX MX2007008833A patent/MX2007008833A/en not_active Application Discontinuation
- 2006-01-20 EP EP06718892A patent/EP1838291A4/en not_active Withdrawn
- 2006-01-20 TW TW095102217A patent/TW200640497A/en unknown
- 2006-01-20 WO PCT/US2006/001887 patent/WO2006078811A2/en active Application Filing
-
2007
- 2007-07-19 IL IL184735A patent/IL184735A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101137352A (en) | 2008-03-05 |
KR20070116588A (en) | 2007-12-10 |
EP1838291A2 (en) | 2007-10-03 |
AR062647A1 (en) | 2008-11-26 |
EP1838291A4 (en) | 2008-12-03 |
AU2006206423A1 (en) | 2006-07-27 |
CA2595470A1 (en) | 2006-07-27 |
WO2006078811A2 (en) | 2006-07-27 |
MX2007008833A (en) | 2008-03-25 |
IL184735A0 (en) | 2007-12-03 |
WO2006078811A3 (en) | 2007-03-01 |
BRPI0614021A2 (en) | 2011-03-01 |
JP2008528494A (en) | 2008-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200640497A (en) | Pharmaceutical formulations and methods of use | |
CA3094580C (en) | Oral formulations of cytidine analogs and methods of use thereof | |
MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
WO2007149406A8 (en) | Modified coagulation factor ix polypeptides and use thereof for treatment | |
MY149623A (en) | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation | |
WO2007092620A3 (en) | Stable formulations, and methods of their preparation and use | |
NO20070887L (en) | Granular pharmaceutical formulation with time-limited release for oral administration, and intraoral rapid disintegrating tablet containing the preparation | |
AR068185A1 (en) | COMPOSITIONS OF LAMOTRIGIN ORAL DISINTEGRATION TABLETS | |
MY161078A (en) | Topical formulation for a jak inhibitor | |
MXPA06013133A (en) | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction. | |
WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
TW200806289A (en) | Sustained-release formulation of zonisamide | |
MX2010004388A (en) | Parathyroid hormone formulations and uses thereof. | |
WO2007018588A8 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
PT2459153E (en) | Pharmaceutical or cosmetic or dietetic composition for promoting a hair pigmentation effect | |
IL195931A0 (en) | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production | |
WO2009004995A1 (en) | Method of fixing and expressing physiologically active substance | |
MX2009010689A (en) | Novel formulations for delivery of antiviral peptide therapeutics. | |
HK1142823A1 (en) | Formulations for the oral administration of therapeutic agents and related methods | |
AR048318A1 (en) | ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA | |
WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use |